While Revance Therapeutics Inc has underperformed by -3.87%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RVNC fell by -86.96%, with highs and lows ranging from $37.98 to $4.10, whereas the simple moving average fell by -64.05% in the last 200 days.
On January 29, 2024, Mizuho Downgraded Revance Therapeutics Inc (NASDAQ: RVNC) to Neutral. A report published by Goldman on January 09, 2024, Downgraded its rating to ‘Neutral’ for RVNC. Exane BNP Paribas also Upgraded RVNC shares as ‘Neutral’, setting a target price of $20 on the company’s shares in a report dated August 16, 2023. Morgan Stanley Initiated an Equal-Weight rating on October 11, 2022, and assigned a price target of $27. Goldman initiated its ‘Buy’ rating for RVNC, as published in its report on September 22, 2022. Wells Fargo’s report from October 25, 2021 suggests a price prediction of $17 for RVNC shares, giving the stock a ‘Equal Weight’ rating. Needham also rated the stock as ‘Buy’.
Analysis of Revance Therapeutics Inc (RVNC)
Further, the quarter-over-quarter increase in sales is 39.82%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Revance Therapeutics Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -2096.78% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.29, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and RVNC is recording an average volume of 1.76M. On a monthly basis, the volatility of the stock is set at 6.39%, whereas on a weekly basis, it is put at 7.72%, with a loss of -10.79% over the past seven days. Furthermore, long-term investors anticipate a median target price of $14.91, showing growth from the present price of $3.97, which can serve as yet another indication of whether RVNC is worth investing in or should be passed over.
How Do You Analyze Revance Therapeutics Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 8.64%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 75.45% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
RVNC shares are owned by institutional investors to the tune of 75.45% at present.
